Turkiye Klinikleri Journal of Health Sciences

.: REVIEW
Düşük FODMAP Diyetine Güncel Yaklaşımlar
Current Approaches to Low FODMAP Diet
Öykü Peren TÜRK FİDANa,b, Zehra BÜYÜKTUNCERb
aAnkara Yıldırım Beyazıt Üniversitesi Sağlık Bilimleri Fakültesi, Beslenme ve Diyetetik Bölümü, Ankara, TÜRKİYE
bHacettepe Üniversitesi Sağlık Bilimleri Fakültesi, Beslenme ve Diyetetik Bölümü, Ankara, TÜRKİYE
Turkiye Klinikleri J Health Sci. 2021;6(1):128-38
doi: 10.5336/healthsci.2020-74727
Article Language: TR
Full Text
ÖZET
FODMAP fermente edilebilir oligosakkaritler, disakkaritler, monosakkaritler ve poliollerin baş harflerinden oluşan bir terimdir. FODMAP grubunda oligosakkaritlerden fruktan ve galaktanlar, disakkaritlerden laktoz, monosakkaritlerden fruktoz, poliollerden ise sorbitol ve mannitol ele alınmaktadır. FODMAP bileşenleri, ince bağırsakta zayıf emilen, kolona ulaşabilen, kolonda bakteriler tarafından hızlı fermente edilebilen, küçük ve dolayısıyla ozmotik olarak aktif moleküllerdir. Diyetle FODMAP alımı, kolonik gaz oluşturabilmekte, fermantasyon ile birlikte ozmotik yükü arttırabilmekte, bağırsak motilitesini etkileyebilmekte ve immün aktivasyon mekanizmaları ile gastrointestinal semptomların ortaya çıkmasına yol açabilmektedir. Bu karbonhidratların özellikle irritabl bağırsak sendromunun (İBS) ve bazı gastrointestinal hastalıkların semptomlarını arttırabildiği düşünülmektedir. Düşük FODMAP diyeti ise fonksiyonel gastrointestinal semptomları azaltmaya yönelik bir diyet olup, ön aşama, kısıtlayıcı aşama ve FODMAP ile yeniden tanıştırma aşamalarından oluşmaktadır. Düşük FODMAP diyetinin İBS semptomlarını azaltabileceği gösterilmiş; Crohn hastalığı, ülseratif kolit, çölyak tanısı olmayan gluten duyarlılığı, divertikülit, fonksiyonel dispepsi, kolik ve çocukluktaki abdominal ağrı semptomları üzerinde yararlı etkiler oluşturabileceğine dair kanıtlar bulunmuştur. Buna karşın, düşük FODMAP diyetinin uzun süre uygulamalarının bağırsak mikrobiyotası üzerinde oluşturacağı olumsuz etkiler ve yetersiz posa alımının neden olacağı riskler iyi değerlendirilmelidir. Bu derlemenin amacı, FODMAP grubunda yer alan karbonhidratların gastrointestinal semptomlarla ilişkisinin incelenmesi ve düşük FODMAP diyet önerilerinin oluşturulmasıdır.

Anahtar Kelimeler: Fermente edilebilir oligosakkaritler; disakkaritler; monosakkaritler; polioller; FODMAP; diyet; gastrointestinal hastalıklar
ABSTRACT
FODMAP is a term consisting of the initials of fermentable oligosaccharides, disaccharides, monosaccharides and polyols. In the FODMAP group, fructane and galactans from oligosaccharides, lactose from disaccharides, fructose from monosaccharides, sorbitol and mannitol from polyols are discussed. FODMAP components are small, and therefore osmotically active, molecules that are poorly absorbed in the small intestine, which can reach the colon, can be quickly fermented by bacteria in the colon. Dietary FODMAP intake can produce colonic gas, increase osmotic load with fermentation, affect bowel motility, and cause immune activation mechanisms and gastrointestinal symptoms. These carbohydrates are thought to increase the symptoms of irritable bowel syndrome (IBS) and some gastrointestinal diseases. The low FODMAP diet is aimed at reducing functional gastrointestinal symptoms, consisting of the pre-stage, restrictive stage, and re-introduction to FODMAP. A low FODMAP diet has been shown to reduce IBS symptoms; evidence has been found to have beneficial effects on Crohn's disease, ulcerative colitis, gluten sensitivity without celiac diagnosis, diverticulitis, functional dispepsy, colic and abdominal pain in childhood. However, the adverse effects of longterm administration of low FODMAP diet on the intestinal microbiota and the risks of insufficient fiber intake should be well evaluated. The aim of this review is to investigate the relationship between carbohydrates in the FODMAP group and gastrointestinal symptoms and to establish low FODMAP dietary recommendations.

Keywords: Fermentable oligosaccharides; disaccharides; monosaccharides; polyols; FODMAP; diet; gastrointestinal diseases
REFERENCES:
  1. Tokay A. Karbonhidratlar: Sindirim ve Emilimi. Özenoğlu A, editör. Beslenmenin Esasları ve Sağlığın Korunmasında Beslenme. 1. Baskı. Ankara: Hatiboğlu Yayınevi; 2016. p. 335-408.
  2. Nantel G. Carbohydrates in human nutrition. Food Nutrition and Agriculture. 1999:6-10.[Link] 
  3. Gibson PR, Shepherd SJ. Evidence-based dietary management of functional gastrointestinal symptoms: The FODMAP approach. J Gastroenterol Hepatol. 2010;25(2):252-8.[Crossref] [PubMed] 
  4. Barrett JS, Gibson PR. Development and validation of a comprehensive semi-quantitative food frequency questionnaire that includes FODMAP intake and glycemic index. J Am Diet Assoc. 2010;110(10):1469-76.[Crossref] [PubMed] 
  5. Aksoy M. Beslenme Biyokimyası. 1. Baskı. Ankara: Hatiboğlu Yayınları; 2011.
  6. Biesiekierski JR, Rosella O, Rose R, Liels K, Barrett JS, Shepherd SJ, et al. Quantification of fructans, galacto-oligosacharides and other short-chain carbohydrates in processed grains and cereals. J Hum Nutr Diet. 2011;24(2):154-76.[Crossref] [PubMed] 
  7. Staudacher HM, Irving PM, Lomer MC, Whelan K. Mechanisms and efficacy of dietary FODMAP restriction in IBS. Nat Rev Gastroenterol Hepatol. 2014;11(4):256-66.[Crossref] [PubMed] 
  8. Nanda R, Shu LH, Thomas JR. A FODMAP Diet Update: Craze or Credible? Pract Gastroenterol. 2012;112:37.[Link] 
  9. Tuck CJ, Muir JG, Barrett JS, Gibson PR. Fermentable oligosaccharides, disaccharides, monosaccharides and polyols: role in irritable bowel syndrome. Expert Rev Gastroenterol Hepatol. 2014;8(7):819-34.[Crossref] [PubMed] 
  10. Dugum M, Barco K, Garg S. Managing irritable bowel syndrome: The low-FODMAP diet. Cleve Clin J Med. 2016;83(9):655-62.[Crossref] [PubMed] 
  11. Khan MA, Nusrat S, Khan MI, Nawras A, Bielefeldt K. Low-FODMAP Diet for Irritable Bowel Syndrome: Is It Ready for Prime Time? Dig Dis Sci. 2015;60(5):1169-77.[Crossref] [PubMed] 
  12. Muir JG, Rose R, Rosella O, Liels K, Barrett JS, Shepherd SJ, et al. Measurement of short-chain carbohydrates in common Australian vegetables and fruits by high-performance liquid chromatography (HPLC). J Agric Food Chem. 2009;57(2):554-65.[Crossref] [PubMed] 
  13. Murray K, Wilkinson-Smith V, Hoad C, Costigan C, Cox E, Lam C, et al. Differential effects of FODMAPs (fermentable oligo-, di-, mono-saccharides and polyols) on small and large intestinal contents in healthy subjects shown by MRI. Am J Gastroenterol. 2014;109(1):110-9.[Crossref] [PubMed] [PMC] 
  14. Barrett JS. Extending our knowledge of fermentable, short-chain carbohydrates for managing gastrointestinal symptoms. Nutr Clin Pract. 2013;28(3):300-6.[Crossref] [PubMed] 
  15. Barrett JS, Gearry RB, Muir JG, Irving PM, Rose R, Rosella O, et al. Dietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon. Aliment Pharmacol Ther. 2010;31(8):874-82.[Crossref] [PubMed] 
  16. Eswaran S. Low FODMAP in 2017: Lessons learned from clinical trials and mechanistic studies. Neurogastroenterol Motil. 2017;29(4).[Crossref] [PubMed] 
  17. Hill P, Muir JG, Gibson PR. Controversies and Recent Developments of the Low-FODMAP Diet. Gastroenterol Hepatol (N Y). 2017;13(1):36-45.[PubMed] [PMC] 
  18. McIntosh K, Reed DE, Schneider T, Dang F, Keshteli AH, De Palma G, et al. FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial. Gut. 2017;66(7):1241-51. Erratum in: Gut. 2019;68(7):1342.[Crossref] [PubMed] 
  19. Kortlever T, Hebblethwaite C, Leeper J, O'Brien L, Mulder C, Gearry RB, et al. Low FODMAP diet efficacy in IBS patients-what is the evidence and what else do we need to know? N Z Med J. 2016;129(1442):75-83.[PubMed] 
  20. Barrett JS, GIbson PR. Clinical ramifications of malabsorption of fructose and other short-chain carbohydrates. Pract Gastroenterol. 2007;31(8):51-65.[Link] 
  21. University M. Monash University Low FODMAP Diet Guide.[Link] 
  22. Barrett JS. How to institute the low-FODMAP diet. J Gastroenterol Hepatol. 2017;32 Suppl 1:8-10.[Crossref] [PubMed] 
  23. Tuck C, Barrett J. Re-challenging FODMAPs: the low FODMAP diet phase two. J Gastroenterol Hepatol. 2017;32 Suppl 1:11-5.[Crossref] [PubMed] 
  24. Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146(1):67-75.e5.[Crossref] [PubMed] 
  25. Chumpitazi BP, Cope JL, Hollister EB, Tsai CM, McMeans AR, Luna RA, et al. Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome. Aliment Pharmacol Ther. 2015;42(4):418-27.[Crossref] [PubMed] [PMC] 
  26. Arslan N. İrritabl barsak sendromunda prebiyotik ve probiyotiklerin kullanımı. Kara A, Coşkun T, editörler. Teoriden Kliniğe Prebiyotikler Probiyotikler. 1. Baskı. İstanbul: Akademi Yayınevi; 2014. p.257-71.
  27. Yao CK, Tuck CJ. The clinical value of breath hydrogen testing. J Gastroenterol Hepatol. 2017;32 Suppl 1:20-22.[Crossref] [PubMed] 
  28. Mazzawi T, Hausken T, Gundersen D, El-Salhy M. Dietary guidance normalizes large intestinal endocrine cell densities in patients with irritable bowel syndrome. Eur J Clin Nutr. 2016;70(2):175-81.[Crossref] [PubMed] [PMC] 
  29. Böhn L, Störsrud S, Liljebo T, Collin L, Lindfors P, Törnblom H, et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology. 2015;149(6):1399-1407.e2.[Crossref] [PubMed] 
  30. Pedersen N, Ankersen DV, Felding M, Wachmann H, Végh Z, Molzen L, et al. Low-FODMAP diet reduces irritable bowel symptoms in patients with inflammatory bowel disease. World J Gastroenterol. 2017;23(18):3356-66.[Crossref] [PubMed] [PMC] 
  31. Gibson PR, Shepherd SJ. Personal view: food for thought--western lifestyle and susceptibility to Crohn's disease. The FODMAP hypothesis. Aliment Pharmacol Ther. 2005;21(12):1399-409.[Crossref] [PubMed] 
  32. Gearry RB, Irving PM, Barrett JS, Nathan DM, Shepherd SJ, Gibson PR, et al. Reduction of dietary poorly absorbed short-chain carbohydrates (FODMAPs) improves abdominal symptoms in patients with inflammatory bowel disease-a pilot study. J Crohns Colitis. 2009;3(1):8-14.[Crossref] [PubMed] 
  33. Donnellan CF, Yann LH, Lal S. Nutritional management of Crohn's disease. Therap Adv Gastroenterol. 2013;6(3):231-42.[Crossref] [PubMed] [PMC] 
  34. Petrarca L, Nenna R, Mastrogiorgio G, Florio M, Brighi M, Pontone S, et al. Dyspepsia and celiac disease: Prevalence, diagnostic tools and therapy. World J Methodol. 2014;4(3):189-96.[Crossref] [PubMed] [PMC] 
  35. Biesiekierski JR, Peters SL, Newnham ED, Rosella O, Muir JG, Gibson PR, et al. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology. 2013;145(2):320-8.e1-3.[Crossref] [PubMed] 
  36. Zanini B, Marullo M, Ricci C, Lanzarotto F, Lanzini A. Sa1989 non celiac gluten sensitivity (NCGS) is outnumbered by FODMAPs sensitivity in patients spontaneously adhering to gluten free diet (GFD): a two stage double blind prospective study. Gastroenterology. 2014;146(5):S-348.[Crossref] 
  37. Krigel A, Lebwohl B. Nonceliac Gluten Sensitivity. Adv Nutr. 2016;7(6):1105-10.[Crossref] [PubMed] [PMC] 
  38. Croagh C, Shepherd SJ, Berryman M, Muir JG, Gibson PR. Pilot study on the effect of reducing dietary FODMAP intake on bowel function in patients without a colon. Inflamm Bowel Dis. 2007;13(12):1522-8.[Crossref] [PubMed] 
  39. Uno Y, van Velkinburgh JC. Logical hypothesis: Low FODMAP diet to prevent diverticulitis. World J Gastrointest Pharmacol Ther. 2016;7(4):503-12.[Crossref] [PubMed] [PMC] 
  40. Tan VP. The low-FODMAP diet in the management of functional dyspepsia in East and Southeast Asia. J Gastroenterol Hepatol. 2017;32 Suppl 1:46-52.[Crossref] [PubMed] 
  41. Halmos EP. Role of FODMAP content in enteral nutrition-associated diarrhea. J Gastroenterol Hepatol. 2013;28 Suppl 4:25-8.[Crossref] [PubMed] 
  42. Iacovou M, Mulcahy EC, Truby H, Barrett JS, Gibson PR, Muir JG, et al. Reducing the maternal dietary intake of indigestible and slowly absorbed short-chain carbohydrates is associated with improved infantile colic: a proof-of-concept study. J Hum Nutr Diet. 2018;31(2):256-65.[Crossref] [PubMed] 
  43. Iacovou M. Adapting the low FODMAP diet to special populations: infants and children. J Gastroenterol Hepatol. 2017;32 Suppl 1:43-5.[Crossref] [PubMed] 
  44. Lis D, Ahuja KD, Stellingwerff T, Kitic CM, Fell J. Case Study: Utilizing a Low FODMAP Diet to Combat Exercise-Induced Gastrointestinal Symptoms. Int J Sport Nutr Exerc Metab. 2016;26(5):481-7.[Crossref] [PubMed] 
  45. Bennet SMP, Böhn L, Störsrud S, Liljebo T, Collin L, Lindfors P, et al. Multivariate modelling of faecal bacterial profiles of patients with IBS predicts responsiveness to a diet low in FODMAPs. Gut. 2018;67(5):872-81.[Crossref] [PubMed] 
  46. Staudacher HM, Lomer MC, Anderson JL, Barrett JS, Muir JG, Irving PM, et al. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr. 2012;142(8):1510-8.[Crossref] [PubMed] 
  47. Halmos EP, Christophersen CT, Bird AR, Shepherd SJ, Muir JG, Gibson PR, et al. Consistent Prebiotic Effect on Gut Microbiota With Altered FODMAP Intake in Patients with Crohn's Disease: A Randomised, Controlled Cross-Over Trial of Well-Defined Diets. Clin Transl Gastroenterol. 2016;7(4):e164.[Crossref] [PubMed] [PMC] 
  48. Staudacher HM, Lomer MCE, Farquharson FM, Louis P, Fava F, Franciosi E, et al. A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial. Gastroenterology. 2017;153(4):936-47.[Crossref] [PubMed] 
  49. Satherley R, Howard R, Higgs S. Disordered eating practices in gastrointestinal disorders. Appetite. 2015;84:240-50.[Crossref] [PubMed] 
  50. Catassi G, Lionetti E, Gatti S, Catassi C. The Low FODMAP Diet: Many Question Marks for a Catchy Acronym. Nutrients. 2017;9(3):292.[Crossref] [PubMed] [PMC] 

.: Up To Date

.: Process List

Login



Contact


Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com